Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Stomach Neoplasms 6Gastritis 5Lymphoma, B-Cell, Marginal Zone 4Dyspepsia 4Peptic Ulcer 3Lymphoma 3Neoplasms 2Stomach Ulcer 1Skin Neoplasms 1Pseudomyxoma Peritonei 1Neutropenia 1Neoplasms, Plasma Cell 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Leukemia 1Infections 1Hematologic Neoplasms 1Helicobacter Infections 1Head and Neck Neoplasms 1Glioblastoma 1Gastritis Dyspepsia Helicobacter Pylori Infection Gastric Cancer Peptic Ulcer 1Fever 1Familial primary gastric lymphoma 1Cystectomy 1Chemotherapy Effect 1Brain Neoplasms 1Astrocytoma 1Appendiceal Neoplasms 1Agammaglobulinemia 1

Interventions

enzalutamide 2sipuleucel-T 1Vancomycin 1Metronidazole 1Docetaxel 1Ciprofloxacin 1Amoxicillin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Castration-Resistant Prostate Cancer (mCRPC) × Amoxicillin × Clear all
NCT06126731 2025-11-24

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Institute of Cancer Research, United Kingdom

Phase 1/2 Recruiting
39 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡